Shares of Autolus Therapeutics (NASDAQ: AUTL) tanked by more than 20% in pre-market trading on Friday after the clinical-stage biopharmaceutical company announced the pricing of its public offering.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Autolus will offer 75 million American Depositary Shares (ADS) in the United States representing 75 million ordinary shares at a price of $2.00 per ADS, for total gross proceeds of $150 million.
Autolus scores a Strong Buy consensus rating from Wall Street analysts based on four unanimous Buys.
